HEPATIC CIRRHOSIS
Clinical trials for HEPATIC CIRRHOSIS explained in plain language.
Never miss a new study
Get alerted when new HEPATIC CIRRHOSIS trials appear
Sign up with your email to follow new studies for HEPATIC CIRRHOSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to halt liver scarring in early trial
Disease control CompletedThis study tests an experimental drug called AZD2389 in people with liver fibrosis (scarring) and compensated cirrhosis (early-stage liver damage). The goal is to check the drug's safety and how the body handles it. About 40 adults with liver disease will receive either AZD2389 o…
Matched conditions: HEPATIC CIRRHOSIS
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill combo aims to cure hepatitis c in just 8 weeks
Disease control CompletedThis study tested a new combination of two antiviral pills, bemnifosbuvir and ruzasvir, taken once daily for 8 weeks in 275 adults with chronic hepatitis C. The main goal was to see if the virus was still undetectable 12 weeks after treatment ended. The trial is now complete, and…
Matched conditions: HEPATIC CIRRHOSIS
Phase: PHASE2 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug AZD2389 targets scarred livers in tiny early trial
Knowledge-focused CompletedThis early study tests whether a single dose of the experimental drug AZD2389 can attach to a protein called FAP in the liver. Twelve adults with advanced liver scarring (fibrosis) will get a PET scan before and after taking the drug to see if it binds to its target. The goal is …
Matched conditions: HEPATIC CIRRHOSIS
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC